About this trial
The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood.
Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not.
All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today.
Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.
Eligibility criteria
Qualifiers
Age > 18 years
ILLIC (as determined during manual chart review)
Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9
Current owner of an iOS- or Android-compatible smartphone
Disqualifiers
Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9
Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or
Self-report of cognitive difficulties that impair functional independence
Trial design
Treatments tested in this trial
- Behavioral Activation Therapy App
- Treatment as Usual
Treatment groups
Sponsors and collaborators
Medical University of South Carolina
Lead sponsor
National Cancer Institute (NCI)
Collaborator